Cecurux Tablet (Dobesilate Calcium Hydrate)

Adult dose

Adults: Administer the following doses of calcium dobesilate orally. 1. Vascular lesions and retinopathy: 500 ∼ 1000 mg per day 2. Venous disease: Administer 750 mg per day for 1 ∼ 3 weeks, then administer 500 mg per day. Take after meals with plenty of fluids. Adjust the dose as appropriate according to age and symptoms.

This medicine should not be used in patients who are allergic to this drug or its components. Furthermore, since this medicine contains lactose, it should not be taken by patients with genetic issues such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption. Caution should be exercised when using this drug in patients with impaired renal function. Since this medication is excreted through the kidneys, dosage adjustments may be required for patients with renal failure. Patients with liver dysfunction should also be careful, and if liver enzyme levels increase, the benefits of treatment should be reassessed. This medication contains sodium bisulfite, which may cause asthmatic attacks or severe allergic reactions in patients allergic to sulfites or those with asthma, so caution is needed. During the course of treatment, symptoms such as headache, abdominal pain, nausea, diarrhea, vomiting, arthralgia, and myalgia may commonly occur. Rarely, serious side effects such as a decrease in blood cell count may occur, and if high fever, sore throat, or signs of infection appear, the patient should consult a physician immediately. If a hypersensitivity reaction occurs, the medication should be discontinued immediately, and in severe cases, anaphylactic shock may occur. The effects on driving or operating machinery are not known, so caution is advised. Regarding pregnancy, experience with this medication is limited, so it is advisable to avoid use, and during breastfeeding, as this drug is excreted in small amounts into breast milk, either discontinuing the medication or stopping breastfeeding is recommended. Safety and efficacy in pediatric patients have not been sufficiently studied. There are no specific precautions for elderly patients aged 65 years and older, but general health status should be considered. This medication may influence certain clinical test results, so it is important to inform healthcare professionals before testing. In case of overdose, there are no specific symptoms reported, but general emergency treatment is necessary.

• Agranulocytosis
• neutropenia
• leukopenia
• skin rash
• allergic dermatitis
• itching
• urticaria
• facial swelling
• anaphylactic reaction
• headache

This medication must be stored in a tightly sealed container to avoid exposure to air or moisture. It is best to maintain a storage temperature between 1 to 30 degrees Celsius.

Appearance

White rectangular tablet

Package unit

90 tablets (10 tablets/PTP packaging × 9 packs)